Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials.
about
TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative diseaseTranscription-based prediction of response to IFNbeta using supervised computational methodsMultiple sclerosis-a quiet revolutionInterferon-beta1b treatment modulates cytokines in patients with primary progressive multiple sclerosisInduction of tumor necrosis factor-alpha (TNF-alpha) by interleukin-12 p40 monomer and homodimer in microglia and macrophagesIs there a role for plant-made vaccines in the prevention of HIV/AIDS?Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.How implementation of systems biology into clinical trials accelerates understanding of diseases.Specific immunotherapy of experimental myasthenia gravis by a novel mechanism.Eye disorders in patients with multiple sclerosis: natural history and management.Vaccines against myasthenia gravis.Infection with Theiler's murine encephalomyelitis virus directly induces proinflammatory cytokines in primary astrocytes via NF-kappaB activation: potential role for the initiation of demyelinating disease.Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies.Gene therapy in autoimmune, demyelinating disease of the central nervous system.Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines.Orally delivered malaria vaccines: not too hard to swallow.The safety of etanercept for the treatment of plaque psoriasis.Infliximab in the treatment of Crohn's disease.Infliximab for the treatment of early rheumatoid arthritis.Intrathecal T-cell clonal expansions in patients with multiple sclerosis.Genomics and new targets for multiple sclerosis.Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides.Liposome-encapsulated peptides protect against experimental allergic encephalitisTherapeutic Advances and Future Prospects in Progressive Forms of Multiple SclerosisRole of cytokine p40 family in multiple sclerosisEnhancing the ability of experimental autoimmune encephalomyelitis to serve as a more rigorous model of multiple sclerosis through refinement of the experimental designClinical, pathological, and immunologic aspects of the multiple sclerosis model in common marmosets (Callithrix jacchus).Clinically validated approaches to the treatment of autoimmune diseases.Pathogenic mechanisms and experimental models of multiple sclerosis.Preclinical models of multiple sclerosis in nonhuman primates.Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challenges.Safety of biologic therapy in rheumatoid arthritis.Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis.Biologic therapies: lessons from multiple sclerosis.Monoclonal antibodies in neuroinflammatory diseases.New findings and old controversies in the research of multiple sclerosis and its model experimental autoimmune encephalomyelitis.Review of laquinimod and its therapeutic potential in multiple sclerosis.How do we manage and treat a patient with multiple sclerosis at risk of tuberculosis?Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates.Gaps Between Aims and Achievements in Therapeutic Modification of Neuronal Damage ("Neuroprotection").
P2860
Q21093232-6B209817-BBD3-4483-99AA-B68B1BFA6A39Q24809619-3481F579-FD75-40BF-B533-719226EF8DCDQ26826930-7D67D09D-A41E-44C0-9D93-C54A180F096FQ28272201-606ADEB1-5F35-4134-AC48-E1C38F06BEAAQ28506067-CFC28873-A25D-4D80-A3EE-CB1B1FEF0F3FQ30350670-538EB34C-330A-422D-84F4-B7F696F1192FQ30699740-3F22BD06-DA78-40F0-BAB7-9A4F1A2741B7Q33814843-B071421F-E542-4969-B239-F5C6E4ED8235Q33831279-00A6F081-4D2A-4E0D-AEDF-C1C57D3F02CAQ34399820-903D6FA4-B2BB-4008-B6CF-3A2AC8044DFBQ34433908-EFD2A227-A71A-46FD-A5B5-FABA77D71023Q34996480-21D90997-8766-40DD-B1CF-C3CD6881EF1FQ35094706-C76DF5BA-0062-447D-8B2D-BBAF2B10F1A8Q35122159-635FA8A7-CC71-4AF6-8E7D-CF4D4C8424AEQ35861182-0F155E99-2788-473F-BDF5-98A4FAAB88B0Q35907014-B0D635FE-E070-42B7-A9C1-154DD5A40468Q35919214-2012D8D6-AB8C-4F00-9C6A-C2117EDC60A5Q35919228-8672C353-B5D3-4969-81AE-CAD15AE79D95Q36099482-6E0DA1E3-5FF3-48A5-8B8B-67583B81430AQ36108869-37AD8F50-965F-4651-BE42-EA4F24AB07B4Q36120827-B871221B-15EF-4223-99C4-1C203A06F1C6Q36327377-950EFA3B-0AFB-4D29-8D27-4339F2438E68Q36482892-0D568B30-4E94-4E9B-A13B-3F73FF100879Q36484443-DAF5C96D-6C45-4484-A2EB-BA6750D5A46DQ36943381-1DB3B74A-1CFA-40FC-922E-48C3AEAC1B18Q37243842-26E57166-263B-4021-A432-AEE2CD847709Q37428522-3985A6DE-6103-4DA8-AF97-2E17979988E7Q37668612-6269AF52-3C01-44CC-B6D2-EC5508E6749CQ37728003-E2CA8C72-8D9A-4150-BA8C-A14CBF1B7F48Q37754657-C5814445-5D8C-4C14-9CE4-7DACE317E741Q37814815-9131D2CD-0579-4234-A5C2-A1A858E50B04Q37944433-125C19CC-DF92-4AFE-AE1C-6F3EC8ED9CDEQ37968620-C2505B28-EAC5-42AC-9B08-6FCE8B2D6EEBQ38026399-F6A5ADC3-EB3E-467F-BD9F-FE4E78DB6F53Q38092121-1BBC88CA-5AF5-444B-AEC7-AB06994CE6E0Q38103283-FDF75E9C-1F33-477D-B7F8-752A1346B7DDQ38161575-D4BDE97F-5A91-4D7D-B767-01D75C7BF654Q38252979-E8D7DB3A-81B6-474A-B417-7E549B00B766Q38286209-1385570A-A311-43E9-BBDA-FCC6D0986FE3Q38379260-637955BB-8BEC-424A-B1A5-4BD5CA916E03
P2860
Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Therapeutic approaches in mult ...... interrupted treatment trials.
@ast
Therapeutic approaches in mult ...... interrupted treatment trials.
@en
Therapeutic approaches in mult ...... interrupted treatment trials.
@nl
type
label
Therapeutic approaches in mult ...... interrupted treatment trials.
@ast
Therapeutic approaches in mult ...... interrupted treatment trials.
@en
Therapeutic approaches in mult ...... interrupted treatment trials.
@nl
prefLabel
Therapeutic approaches in mult ...... interrupted treatment trials.
@ast
Therapeutic approaches in mult ...... interrupted treatment trials.
@en
Therapeutic approaches in mult ...... interrupted treatment trials.
@nl
P1433
P1476
Therapeutic approaches in mult ...... interrupted treatment trials.
@en
P2093
Reinhard Hohlfeld
P304
P356
10.2165/00063030-200216030-00003
P50
P577
2002-01-01T00:00:00Z
P6179
1010802408